CAR-T has a lot of promise, but some big challenges remain, experts at BIO, ASCO say
Many issues around CAR-T remain to be hashed out, but many experts pointed to infrastructure and clinics' capabilities as crucial.
Many issues around CAR-T remain to be hashed out, but many experts pointed to infrastructure and clinics' capabilities as crucial.
CAR-Ts have generated excitement, but bispecific monoclonal antibodies may continue to have a competitive edge in some cases.
Progression-free survival rates from bb2121 in multiple myeloma still impress despite investor reaction.
Experts went into the nitty-gritty aspects of how the community oncology setting can implement precision medicine trials.
Interim data from the Phase I data show 77 percent overall response rate, including 74 percent confirmed responses.